Your browser doesn't support javascript.
loading
Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero, Angel Mauricio; Borges, Kleiton Silva; da Silva Silveira, Vanessa; Lira, Regia Caroline Peixoto; de Paula Gomes Queiroz, Rosane; Valera, Fabiana Cardoso Pereira; Scrideli, Carlos Alberto; Umezawa, Kazuo; Tone, Luiz Gonzaga.
Afiliação
  • Castro-Gamero AM; Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. amcgen@gmail.com
Anticancer Drugs ; 23(6): 638-50, 2012 Jul.
Article em En | MEDLINE | ID: mdl-22382389
ABSTRACT
Osteosarcoma (OS) is the most common primary malignant bone tumor, usually developing in children and adolescents, and is highly invasive and metastatic, potentially developing chemoresistance. Thus, novel effective treatment regimens are urgently needed. This study was the first to investigate the anticancer effects of dehydroxymethylepoxyquinomicin (DHMEQ), a highly specific nuclear factor-κB (NF-κB) inhibitor, on the OS cell lines HOS and MG-63. We demonstrate that NF-κB blockade by DHMEQ inhibits proliferation, decreases the mitotic index, and triggers apoptosis of OS cells. We examined the effects of combination treatment with DHMEQ and cisplatin, doxorubicin, or methotrexate, drugs commonly used in OS treatment. Using the median effect method of Chou and Talalay, we evaluated the combination indices for simultaneous and sequential treatment schedules. In all cases, combination with a chemotherapeutic drug produced a synergistic effect, even at low single-agent cytotoxic levels. When cells were treated with DHMEQ and cisplatin, a more synergistic effect was obtained using simultaneous treatment. For the doxorubicin and methotrexate combination, a more synergistic effect was achieved with sequential treatment using DHMEQ before chemotherapy. These synergistic effects were accompanied by enhancement of chemoinduced apoptosis. Interestingly, the highest apoptotic effect was reached with sequential exposure in both cell lines, independent of the chemotherapeutic agent used. Likewise, DHMEQ decreased cell invasion and migration, crucial steps for tumor progression. Our data suggest that combining DHMEQ with chemotherapeutic drugs might be useful for planning new therapeutic strategies for OS treatment, mainly in resistant and metastatic cases.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzamidas / Neoplasias Ósseas / Osteossarcoma / NF-kappa B / Cicloexanonas / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzamidas / Neoplasias Ósseas / Osteossarcoma / NF-kappa B / Cicloexanonas / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2012 Tipo de documento: Article